Eisai announces Phase 3 Lenvima combination trial analyses in advanced kidney cancer at ESMO 2026

Eisai will present final Phase 3 LITESPARK-011 results for advanced kidney cancer at ESMO in Madrid on October 25, 2026. The study supported recent FDA clearance of Welireg with Lenvima for adults with advanced clear-cell kidney cancer previously treated with immunotherapy. LITESPARK-012 findings, also scheduled for October 25, will assess two investigational first-line regimens against Keytruda with Lenvima in advanced clear-cell kidney cancer. An exploratory LEAP-001 biomarker analysis in advanced or recurrent endometrial cancer will be presented October 23, examining treatment response. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eisai Co. Ltd. published the original content used to generate this news brief via (Ref. ID: 202610150808PR_NEWS_USPR_____NY72423) on October 15, 2026, and is solely responsible for the information contained therein. (C)